1Ngeow YF,Suwanjutha S,Chantarojanasriri T,et al.An asian study on the prevalence of atypical respiratory pathogens in community-acquired pneumonia.Int J Infect Dis,2005,9:144-153.
2Lepow ML,Balassanian N,Emmerich J,et al.Interrelationships of viral,mycoplasmal,and bacterial agents in uncomplicated pneumonia.Am Rev Respir Dis,1968,97:533-545.
3Lim WS,Macfarlane JT,Boswell TC,et al.Study of community acquired pneumonia aetiology(SCAPA) in adults admitted to hospital:implications for management guidelines.Thorax,2001,56:296-301.
4Niederman MS,Mandell LA,Anzueto A,et al.Guidelines for the management of adults with community-acquired pneumonia.Diagnosis,assessment of severity,antimicrobial therapy,and prevention.Am J Respir Crit Care Med,2001,163:1730-1754.
5Heffelfinger JD,Dowell SF,Jorgensen JH,et al.Management of community-acquired pneumonia in the era of pneumococcal resistance:a report from the Drug-Resistant Streptococcus pneumoniae Therapeutic Working Group.Arch Intern Med,2000,160:1399-1408.
6Baudouin SV.The pulmonary physician in critical care 3: critical care management of community acquired pneumonia.Thorax,2002,57:267-271.
7American Thoracic Society.Guidelines for the management of adults with community acquired pneumonia.Am J Respir Crit Care Med,2001,163:1730-1754.
8Fine MJ,Auble TE,Yearly DM,et al.A prediction rule to identify low-risk patients with commu-nity-acquired pneumonia.N Engl J Med,1997,336:243-250.
9Feldman C.Pneumonia in the elderly.Med Clin North Am,2001,85: 1441-1459.
10Marrie TJ.Community-acquired pneumonia in the elderly.Clin Infect Dis,2000,31:1066-1078.
10Mblondeau J. The role of PK/PD parameters to avoid selection and increase of resistance. Mutant prevention concentration[J]. Jottrnal of Chemotherapy,2004,16:14.
